Aimmune Reports Second Quarter 2015 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced financial results for the second quarter and six months ending June 30, 2015.

“This has been a transformational year for Aimmune, and we are proud of the clinical, regulatory, and financial milestones we have achieved over the recent months,” said Stephen Dilly, M.B.B.S., Ph.D., chief executive officer of Aimmune Therapeutics.

Help employers find you! Check out all the jobs and post your resume.

Back to news